GLG News by Ophthalmologists (US)

This was a retrospective clinical study of 21 eyes from 12 patients who identified themselves as being dissatisfied with their visual acuity and were interested either in initial or enhancement refractive surgery in order to improve their acuity. Uncorrected visual acuity was documented in each eye....

Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena.  Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema.  Given its success in cardiology, it is a promising...

This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis.  Blepharitis is a large problem affecting many patients.  This could be a large market opportunity.

Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing.  A 10% reduction in intraocular pressure is not enough to make a clinical...

The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration.  Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy.  If CATT confirms this, it sink Lucentis Sales...

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

I HAVE BEEN PRODICTING THAT A MAJOR PLAYER WOULD BUY EYEONICS SINCE I FIRST STARTED PLACING THE CRYSTALENS IN MY PATIENTS. THE LENS WORKS BUT NEEDED A PRO AT MARKETING. B& L WILL BENIFIT FROM THIS BUY.

MOST TEACHING HOSPITALS LOOK DOWN THEIR ACADEMIC NOSE AT ANYTHING COMMERICAL. THESE SAME SCHOOLS DON'T TEACH DOCTORS HOW TO SURVIVE MUCH LESS SUCEED IN THE PRIVATE SECTOR.

As ophthalmologists, we have been waiting for development of a useful telescopic intraocular lens implant for over 17 years. These lenses have been in FDA trials for years, but never brought to market because of numerous problems with them. A viable telescopic lens implant would give us something to...

This article confirms what I have long suspected.  We doctors spend entirely too much valuable time trying to separate clinical truth from marketing messages.  And many (but not all) of us are tired of hearing our patients complain that they are not using their medicines because they cannot...